Investigational New Drugs

, Volume 33, Issue 2, pp 397–408 | Cite as

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

  • Daniel P. Petrylak
  • Jitendra G. Gandhi
  • William R. Clark
  • Elisabeth Heath
  • Jianqing Lin
  • William K. Oh
  • David B. Agus
  • Bradley Carthon
  • Susan Moran
  • Ning Kong
  • Ajit Suri
  • Michael Bargfrede
  • Glenn Liu


Background: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated orteronel plus DP in mCRPC patients. Methods: Adult men with chemotherapy-naïve mCRPC, serum prostate-specific antigen (PSA) ≥5 ng/mL, and serum testosterone <50 ng/dL received oral orteronel 200 or 400 mg twice-daily (BID) in phase 1 to determine the recommended dose for phase 2, plus intravenous docetaxel 75 mg/m2 every 3 weeks, and oral prednisone 5 mg BID. Phase 2 objectives included safety, pharmacokinetics, and efficacy. Results: In phase 1 (n = 6, orteronel 200 mg; n = 8, orteronel 400 mg), there was one dose-limiting toxicity of grade 3 febrile neutropenia at 400 mg BID. This dose was evaluated further in phase 2 (n = 23). After 4 cycles, 68, 59, and 23 % of patients achieved ≥30, ≥50, and ≥90 % PSA reductions, respectively; median best PSA response was −77 %. Seven of 10 (70 %) RECIST-evaluable patients achieved objective partial responses. Median time to PSA progression and radiographic disease progression was 6.7 and 12.9 months, respectively. Dehydroepiandrosterone-sulfate (DHEA-S) and testosterone levels were rapidly and durably reduced. Common adverse events were fatigue (78 %), alopecia (61 %), diarrhea (48 %), nausea (43 %), dysgeusia (39 %), and neutropenia (39 %). Orteronel and docetaxel pharmacokinetics were similar alone and in combination. Conclusions: Orteronel plus DP was tolerable, with substantial reductions in PSA, DHEA-S, and testosterone levels, and evidence for measurable disease responses.


Genitourinary cancers Prostate cancer Phase 1/2 clinical trial Orteronel Docetaxel Prednisone 



The authors would like to thank the patients who participated in this study and their families, as well as staff at all investigational sites. Stephen Mosley and Emma Landers of FireKite, part of the KnowledgePoint360 Group, an Ashfield Company, provided writing support during the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc., and complied with Good Publication Practice 2 guidelines (Graf C, et al. BMJ 2009;339:b4330).


Employment: NK, SM, AS, MB (Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited).

Consultancy or membership on board of directors or advisory committee: DPP, DBA (Millennium Pharmaceuticals, Inc.), WKO (Bellicum).

Research funding: DPP, EH, WKO, WRC (Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), DPP (Sanofi-Aventis).

Honoraria: WKO (Janssen, Dendreon, Medivation, Sanofi, Astellas).

Conflicts of interest


Disclosure of financial support

This research was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Supplementary material

10637_2014_199_MOESM1_ESM.doc (78 kb)
Supplementary Table 1 Summary of PK parameters for orteronel and docetaxel alone, and in combination (DOC 78 kb)
10637_2014_199_MOESM2_ESM.doc (82 kb)
Supplementary Table 2 Statistical analysis of plasma pharmacokinetics parameters for orteronel and docetaxel, alone and in combination (DOC 81 kb)
10637_2014_199_Fig4_ESM.gif (33 kb)
Supplementary Fig. 1

Change from baseline in median serum levels of (a) DHEA-S and (b) testosterone. DHEA-S, dehydroepiandrosterone-sulfate (GIF 32 kb)

10637_2014_199_MOESM3_ESM.eps (1.1 mb)
High resolution image (EPS 1103 kb)
10637_2014_199_Fig5_ESM.gif (68 kb)
Supplementary Fig. 2

Mean (±SD) plasma concentration-time profiles for (a) orteronel ± docetaxel and (b) docetaxel ± orteronel. SD, standard deviation (GIF 68 kb)

10637_2014_199_MOESM4_ESM.eps (1.1 mb)
High resolution image (EPS 1127 kb)


  1. 1.
    Huang X, Chau CH, Figg WD (2012) Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 5:35CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Acar O, Esen T, Lack NA (2013) New therapeutics to treat castrate-resistant prostate cancer. Sci World J 2013:379641Google Scholar
  3. 3.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520CrossRefPubMedGoogle Scholar
  4. 4.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefPubMedGoogle Scholar
  5. 5.
    Sanofi Aventis US, LLC (2013) TAXOTERE® (docetaxel). Prescribing information (revised December 2013). Available at:
  6. 6.
    Bracarda S, Logothetis C, Sternberg CN, Oudard S (2011) Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 107(Suppl 2):13–20CrossRefPubMedGoogle Scholar
  7. 7.
    Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrinol Relat Cancer 18:R175–R182CrossRefGoogle Scholar
  8. 8.
    Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415CrossRefPubMedGoogle Scholar
  9. 9.
    Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ (2012) Novel options for the treatment of castration-resistant prostate cancer. World J Urol 30:495–503CrossRefPubMedGoogle Scholar
  10. 10.
    Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M (2012) Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 129:115–128CrossRefPubMedGoogle Scholar
  11. 11.
    Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, Asahi S, Furuya S, Tasaka A (2011) Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 19:6383–6399CrossRefPubMedGoogle Scholar
  12. 12.
    Janssen Biotech Inc. (2012) Abiraterone acetate (Zytiga®) Prescribing Information (revised May 2014). Available at:
  13. 13.
    Astella Pharma US Inc. (2012) Enzalutamide (Xtandi®) Prescribing Information (revised September 2014). Available at:
  14. 14.
    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433CrossRefPubMedGoogle Scholar
  15. 15.
    Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992CrossRefPubMedGoogle Scholar
  16. 16.
    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van PH, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRefPubMedGoogle Scholar
  18. 18.
    Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992–8002CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135–2144CrossRefPubMedGoogle Scholar
  20. 20.
    Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB (2014) Phase I/II trial of orteronel (TAK-700)–an investigational 17,20-lyase inhibitor–in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 20:1335–1344CrossRefPubMedGoogle Scholar
  21. 21.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
  22. 22.
    National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Version 4.03Google Scholar
  23. 23.
    Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 13:920–928CrossRefPubMedGoogle Scholar
  25. 25.
    Ferraldeschi R, de Bono J (2013) Agents that target androgen synthesis in castration-resistant prostate cancer. Cancer J 19:34–42CrossRefPubMedGoogle Scholar
  26. 26.
    Leibowitz-Amit R, Joshua AM (2013) The changing landscape in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 7:243–248CrossRefPubMedGoogle Scholar
  27. 27.
    Saad F (2013) Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol 5:201–210CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ (2013) Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 25:406–430CrossRefGoogle Scholar
  29. 29.
    Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14:1307–1316CrossRefPubMedGoogle Scholar
  30. 30.
    Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740–1747CrossRefPubMedGoogle Scholar
  31. 31.
    Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534–1540CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893–900CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G (2011) Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29:2191–2198CrossRefPubMedGoogle Scholar
  34. 34.
    Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14:760–768CrossRefPubMedGoogle Scholar
  35. 35.
    Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH (2009) Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 69:1579–1585CrossRefPubMedGoogle Scholar
  36. 36.
    Guerrero J, Alfaro IE, Gomez F, Protter AA, Bernales S (2013) Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73:1291–1305CrossRefPubMedGoogle Scholar
  37. 37.
    Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287:3777–3787CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick CA, Olmos D, Attard G, de Bono J (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23:2943–2947CrossRefPubMedGoogle Scholar
  40. 40.
    De Wit R, Fizazi K, Jinga V, Efstathiou E, Fong P, Wirth M, Suzuki K, Moran S, Wang L, Akaza H, Nelson J, Scher H, Dreicer R, Borgstein N, Saad F (2014) Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol 32(Suppl_5s):Abstract 5008Google Scholar
  41. 41.
    Dreicer R, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono J, Shi Y, Tejura B, Agus D, Borgstein N, Bellmunt J, Fizazi K (2014) Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). J Clin Oncol 32(Suppl_4):Abstract 7Google Scholar
  42. 42.
    Lu C, Suri A, Prakesh S (2012) Application of physiologically based pharmacokinetic modeling and simulation for waiver of orteronel drug-drug interaction trials. Poster presented at the 19th International Symposium on Microsomes and Drug Interactions and the 12th European ISSX Meeting. ISSX Online Abstracts Suppl 7(1):Abstract P90Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Daniel P. Petrylak
    • 1
  • Jitendra G. Gandhi
    • 2
  • William R. Clark
    • 3
  • Elisabeth Heath
    • 4
  • Jianqing Lin
    • 5
  • William K. Oh
    • 6
  • David B. Agus
    • 7
  • Bradley Carthon
    • 8
  • Susan Moran
    • 9
  • Ning Kong
    • 10
  • Ajit Suri
    • 11
  • Michael Bargfrede
    • 11
  • Glenn Liu
    • 12
  1. 1.Department of MedicineSmilow Cancer Center, Yale University Medical CenterNew HavenUSA
  2. 2.Associates in Oncology and HematologyChatanoogaUSA
  3. 3.Alaska Clinical Research CenterAnchorageUSA
  4. 4.Department of OncologyKarmanos Cancer InstituteDetroitUSA
  5. 5.Department of Medical OncologyThomas Jefferson UniversityPhiladelphiaUSA
  6. 6.Division of Hematology and Medical OncologyMount Sinai HospitalNew YorkUSA
  7. 7.Department of MedicineUniversity of Southern California, Keck School of MedicineLos AngelesUSA
  8. 8.Department of Hematology and Medical OncologyWinship Cancer Institute, Emory UniversityAtlantaUSA
  9. 9.Oncology Clinical Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedCambridgeUSA
  10. 10.Biostatistics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedCambridgeUSA
  11. 11.Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company LimitedCambridgeUSA
  12. 12.Department of MedicineUniversity of Wisconsin Carbone Cancer CenterMadisonUSA

Personalised recommendations